- Home
- SPRY vs BCSF Comparison
SPRY vs BCSF Comparison
Compare SPRY & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- BCSF
- Stock Information
- Founded
- SPRY 2015
- BCSF 2015
- Country
- SPRY United States
- BCSF United States
- Employees
- SPRY N/A
- BCSF N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- SPRY Health Care
- BCSF Finance
- Exchange
- SPRY Nasdaq
- BCSF Nasdaq
- Market Cap
- SPRY 1.6B
- BCSF 978.9M
- IPO Year
- SPRY N/A
- BCSF 2018
- Fundamental
- Price
- SPRY $17.90
- BCSF $15.54
- Analyst Decision
- SPRY Strong Buy
- BCSF Buy
- Analyst Count
- SPRY 4
- BCSF 2
- Target Price
- SPRY $28.75
- BCSF $16.50
- AVG Volume (30 Days)
- SPRY 1.7M
- BCSF 294.1K
- Earning Date
- SPRY 08-05-2025
- BCSF 08-05-2025
- Dividend Yield
- SPRY N/A
- BCSF 10.82%
- EPS Growth
- SPRY N/A
- BCSF N/A
- EPS
- SPRY N/A
- BCSF 1.75
- Revenue
- SPRY $97,122,000.00
- BCSF $284,993,000.00
- Revenue This Year
- SPRY N/A
- BCSF N/A
- Revenue Next Year
- SPRY $170.64
- BCSF N/A
- P/E Ratio
- SPRY N/A
- BCSF $8.89
- Revenue Growth
- SPRY 971120.00
- BCSF N/A
- 52 Week Low
- SPRY $8.91
- BCSF $13.20
- 52 Week High
- SPRY $18.90
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- SPRY 64.52
- BCSF 62.64
- Support Level
- SPRY $17.19
- BCSF $15.43
- Resistance Level
- SPRY $18.22
- BCSF $15.32
- Average True Range (ATR)
- SPRY 0.94
- BCSF 0.23
- MACD
- SPRY 0.02
- BCSF 0.09
- Stochastic Oscillator
- SPRY 94.01
- BCSF 93.05
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.